Targeted Therapy in Hepatocellular CarcinomaReport as inadecuate




Targeted Therapy in Hepatocellular Carcinoma - Download this document for free, or read online. Document in PDF available to download.

International Journal of HepatologyVolume 2011 2011, Article ID 348297, 11 pages

Review ArticleDepartment of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610

Received 18 January 2011; Accepted 1 March 2011

Academic Editor: Thomas Leung

Copyright © 2011 Clarinda W. L. Chua and Su Pin Choo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatocellular carcinoma HCC is one of the commonest cancers worldwide, as well as a common cause of cancer-related death. HCC frequently occurs in the setting of a diseased cirrhotic liver and many patients present at an advanced stage of disease. Together with a poor functional status, this often precludes the use of systemic therapy, especially conventional cytotoxic drugs. Moreover, HCC is known to be a relatively chemo-refractory tumor. There have been many targeted drugs that have shown potential in the treatment of HCC. Many clinical trials have been carried out with many more in progress. They include trials evaluating a single targeted therapy alone, two or more targeted therapy in tandem or a combination of targeted therapy and conventional chemotherapy. In this article, we seek to review some of the more important trials examining the use of targeted therapy in HCC and to look into what the future holds in terms of targeted treatment of HCC.





Author: Clarinda W. L. Chua and Su Pin Choo

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents